Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002810 · ClinicalTrials.gov registry record · Phase 2
High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis
A Phase 2 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002810 is a Phase 2 study that has completed, run by Temple University.
The verdict
NCT00002810, a Phase 2 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having a peripheral stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy to be given so that more plasma cells are killed. By reducing the number of plasma cells, the disease may progress more slowly. PURPOSE: This phase II trial is studying how well giving high-dose melphalan together with peripheral stem cell transplant works in treating patients with primary amyloidosis or amyloidosis associated with multiple myeloma.
Interventions
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- PROCEDURE bone marrow ablation with stem cell support
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-05 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002810
The ClinicalTrials.gov registry entry for NCT00002810 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which melphalan is the first listed.
NCT00002810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002810 about?
NCT00002810 is a clinical study titled "High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Having a peripheral stem cell transplant to replace the blood-forming cells destroyed by chemotherapy, allows higher doses of chemotherapy t...
What is the current status of trial NCT00002810?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-05. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00002810?
The interventions under investigation include: melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), bone marrow ablation with stem cell support (PROCEDURE).
Who is sponsoring clinical trial NCT00002810?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.